The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Open accessAbstract
BACKGROUND: Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma. METHODS: In this phase 2 study, we investigated oral ibrutinib, at a daily dose of 560 mg, in 111 patients with relapsed or refractory mantle-cell lymphoma. Patients were enrolled into two groups: those who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles of bortezomib or had received no prior bortezomib therapy. The primary end point was the overall response rate. Secondary end points were duration of response, progression-free survival, overall survival, and safety. RESULTS: The median age was 68 years, and 86% of patients had intermediate-risk or high-risk mantle-cell lymphoma according to clinical prognostic factors. Patients had received a median of three prior therapies. The most common treatment-related adverse events were mild or moderate diarrhea, fatigue, and nausea. Grade 3 or higher hematologic events were infrequent and included neutropenia (in 16% of patients), thrombocytopenia (in 11%), and anemia (in 10%). A response rate of 68% (75 patients) was observed, with a complete response rate of 21% and a partial response rate of 47%; prior treatment with bortezomib had no effect on the response rate. With an estimated median follow-up of 15.3 months, the estimated median response duration was 17.5 months (95% confidence interval [CI], 15.8 to not reached), the estimated median progression-free survival was 13.9 months (95% CI, 7.0 to not reached), and the median overall survival was not reached. The estimated rate of overall survival was 58% at 18 months. CONCLUSIONS: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01236391.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, it is not selective for BTK, and multiple mechanisms of resistance, including the C481S-BTK mutation, can compromise its efficacy.”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
In the citing paper
“often due to the C481S mutation of BTK, which prevents ibrutinib from forming a covalent bond with BTK and significantly reduces its potency, resulting in median progression-free survival of only ;14 months.8”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
In the citing paper
“often due to the C481S mutation of BTK, which prevents ibrutinib from forming a covalent bond with BTK and significantly reduces its potency, resulting in median progression-free survival of only ;14 months.8”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,236
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Self-citationOptimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
The Non-Hodgkin's Lymphoma Classification Project (1997) · Blood · doi:10.1182/blood.v89.11.3909 · Cited by 2,456
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Self-citationChronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,651
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128
Self-citationHerman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807
Self-citation
Research works printed but not linked: 1
- 10.2307/2281868 · DOI · Paper page
Cited by
Sorted by citations
Items 201–300 of 1,000
Zhao, X., Bodo, J., Sun, D., Durkin, L. M., Lin, J. J., Smith, M. R., & Hsi, E. D. (2014) · British Journal of Haematology · doi:10.1111/bjh.13149 · Cited by 93
Coffey, G., Betz, A., DeGuzman, F. R., Pak, Y., Inagaki, M., Baker, D. C., Hollenbach, S. J., Pandey, A., & Sinha, U. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.218164 · Cited by 95
Clinical Targeting of Mutated and Wild-Type Protein Tyrosine Kinases in Cancer
Drake, J. M., Lee, J. K., & Witte, O. N. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01592-13 · Cited by 94
Ping, L., Ding, N., Shi, Y., Feng, L., Li, J., Liu, Y., Lin, Y., Shi, C., Wang, X., Pan, Z., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16836 · Cited by 94
Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms
Roskoski, R. J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.09.011 · Cited by 94
Brown, J. R., Moslehi, J. J., Ewer, M. S., O'Brien, S. M., Ghia, P., Cymbalista, F., Shanafelt, T. D., Fraser, G. A. M., Rule, S. A., Coutre, S. E., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15690 · Cited by 93
Self-citationCharacterization of ibrutinib-sensitive and -resistant mantle lymphoma cells
Ma, J., Lu, P., Guo, A., Cheng, S., Zong, H., Martin, P., Coleman, M., & Wang, Y. L. (2014) · British Journal of Haematology · doi:10.1111/bjh.12974 · Cited by 90
Self-citationDufner, V., Sayehli, C. M., Chatterjee, M., Hummel, H., Gelbrich, G., Bargou, R. C., & Goebeler, M.-E. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000025 · Cited by 91
Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)
Roskoski, R. J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105422 · Cited by 92
Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features
Shirley, M. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00857-8 · Cited by 92
Mantle cell lymphoma: 2015 update on diagnosis, risk‐stratification, and clinical management
Vose, J. M. (2015) · American Journal of Hematology · doi:10.1002/ajh.24094 · Cited by 89
Precision therapy for lymphoma—current state and future directions
Intlekofer, A. M., & Younes, A. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.137 · Cited by 91
Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies
Rogers, K. A., Mousa, L., Zhao, Q., Bhat, S. A., Byrd, J. C., Boghdadly, Z. E., Guerrero, T., Levine, L. B., Lucas, F. M., Shindiapina, P., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0481-1 · Cited by 90
Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma
Zhang, S. Y., Smith, S. M., Zhang, S. Y., & Wang, Y. L. (2015) · British Journal of Haematology · doi:10.1111/bjh.13427 · Cited by 91
Law, M. F., Ho, R., Cheung, C. K. M., Tam, L. H. P., Ma, K., So, C.-Y., Ip, B. Y. M., So, J., Lai, J. W.-Y., Ng, J., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6484 · Cited by 87
Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!
Dreyling, M. H., Klapper, W., & Rule, S. A. (2018) · Blood · doi:10.1182/blood-2017-08-737502 · Cited by 90
Self-citationRenal Toxicities of Targeted Therapies
Abbas, A., Mirza, M. M., Ganti, A. K., & Tendulkar, K. K. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0368-7 · Cited by 87
Haematological malignancies: at the forefront of immunotherapeutic innovation
Bachireddy, P., Burkhardt, U. E., Rajasagi, M., & Wu, C. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3907 · Cited by 85
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
Martin, P., Bartlett, N. L., Blum, K. A., Park, S. I., Maddocks, K. J., Ruan, J., Ridling, L., Dittus, C. E., Chen, Z., Huang, X., et al. (2019) · Blood · doi:10.1182/blood-2018-11-886457 · Cited by 84
Self-citationIbrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma
Jain, P., Zhao, S., Lee, H. J., Hill, H. A., Ok, C. Y., Kanagal‐Shamanna, R., Hagemeister, F. B., Fowler, N. H., Fayad, L., Yao, Y., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01797 · Cited by 84
Self-citationde Rooij, M. F. M., Kuil, A., Kater, A. P., Kersten, M. J., Pals, S. T., & Spaargaren, M. (2015) · Blood · doi:10.1182/blood-2014-12-619163 · Cited by 87
Byrd, J. C., Smith, S. D., Wagner‐Johnston, N. D., Sharman, J. P., Chen, A. I., Advani, R. H., Augustson, B. M., Marlton, P. V., Commerford, S. R., Okrah, K., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24310 · Cited by 84
Self-citationBuske, C., Hutchings, M., Ladetto, M., Goede, V., Mey, U., Soubeyran, P., Spina, M., Stauder, R., Trněný, M., Wedding, U., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx413 · Cited by 83
Self-citationBurt, R. J., Warcel, D., & Fielding, A. K. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1540828 · Cited by 86
Skarzynski, M., Niemann, C. U., Lee, Y. S., Martyr, S. E., Marić, I., Salem, D., Stetler‐Stevenson, M., Marti, G. E., Calvo, K. R., Yuan, C. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1304 · Cited by 83
Pseudokinases: Update on Their Functions and Evaluation as New Drug Targets
Byrne, D. P., Foulkes, D. M., & Eyers, P. A. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0207 · Cited by 84
The European Hematology Association Roadmap for European Hematology Research: a consensus document
Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Dohner, H., de Wit, T. D., Eichinger, S., Fibbe, W., Green, T., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.136739 · Cited by 81
“This led to collaborative trials with new drugs including temsirolimus, lenalidomide, ibrutinib, bortezomib, and others.(87) It has been clearly demonstrated that outcome depends on response.”
BackgroundMyklebust, J. H., Brody, J., Kohrt, H. E. K., Kolstad, A., Czerwinski, D. K., Wälchli, S., Green, M. R., Trøen, G., Liestøl, K., Beiske, K., et al. (2016) · Blood · doi:10.1182/blood-2016-05-718494 · Cited by 84
Husby, S., Favero, F., Nielsen, C., Sørensen, B. S., Bæch, J., Grell, K., Hansen, J. W., Rodríguez-González, F. G., Haastrup, E. K., Fischer‐Nielsen, A., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0795-z · Cited by 82
Brown, J. R., Harb, W. A., Hill, B. T., Gabrilove, J. L., Sharman, J. P., Schreeder, M. T., Barr, P. M., Foran, J. M., Miller, T., Burger, J. A., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.140806 · Cited by 81
Chiron, D., Dousset, C., Brosseau, C., Touzeau, C., Maïga, S., Moreau, P., Pellat‐Deceunynck, C., Gouill, S. L., & Amiot, M. (2015) · Oncotarget · doi:10.18632/oncotarget.3275 · Cited by 80
Targeting Bruton’s Tyrosine Kinase in CLL
Ahn, I. E., & Brown, J. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.687458 · Cited by 82
Platelet GPVI (Glycoprotein VI) and Thrombotic Complications in the Venous System
Perrella, G., Nagy, M., Watson, S. P., & Heemskerk, J. W. M. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316108 · Cited by 85
Aalipour, A., & Advani, R. H. (2014) · Therapeutic Advances in Hematology · doi:10.1177/2040620714539906 · Cited by 84
Self-citationIbrutinib for B cell malignancies
Novero, A., Ravella, P. M., Chen, Y., Dous, G. V., & Liu, D. (2014) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-3-4 · Cited by 80
Dreger, P., Michallet, M., Bosman, P. V., Dietrich, S., Sobh, M., Boumendil, A., Nagler, A., Scheid, C., Cornelissen, J. J., Niederwieser, D. W., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0207-4 · Cited by 78
Self-citationPhillips, T. J., Barr, P. M., Park, S. I., Kolibaba, K. S., Caimi, P. F., Chhabra, S., Kingsley, E. C., Boyd, T. E., Chen, R., Carret, A., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0655-0 · Cited by 78
Efremov, D. G., Turkalj, S., & Laurenti, L. (2020) · Cancers · doi:10.3390/cancers12061396 · Cited by 85
Natural Molecules Targeting Thioredoxin System and Their Therapeutic Potential
Zhang, J., Duan, D., Osama, A., & Fang, J. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8213 · Cited by 78
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
Wang, M. L., Belada, D., Belada, D., Song, Y., Jurczak, W. J., Kahl, B. S., Paludo, J., Chu, M. P., Kryachok, I., Fogliatto, L., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00690 · Cited by 78
Self-citationB cells in chronic graft-versus-host disease
McManigle, W. C., Youssef, A., & Sarantopoulos, S. (2019) · Human Immunology · doi:10.1016/j.humimm.2019.03.003 · Cited by 81
Drug Resistance in Non-Hodgkin Lymphomas
Klener, P., & Klánová, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062081 · Cited by 78
Advancing Covalent Ligand and Drug Discovery beyond Cysteine
Kim, G., Grams, R. J., & Hsu, K. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00001 · Cited by 84
de Jong, J., Sukbuntherng, J., Skee, D. M., Murphy, J., O'Brien, S. M., Byrd, J. C., James, D. F., Hellemans, P., Loury, D. J., Jiao, J. J., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2708-9 · Cited by 77
Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function
Rigg, R. A., Aslan, J. E., Healy, L. D., Wallisch, M., Thierheimer, M. L. D., Loren, C. P., Pang, J., Hinds, M. T., Gruber, A., & McCarty, O. J. T. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00325.2015 · Cited by 78
NF-κB signaling and its relevance to the treatment of mantle cell lymphoma
Balaji, S., Ahmed, M., Lorence, E., Yan, F., Nomie, K. J., & Wang, M. L. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0621-5 · Cited by 77
Self-citationFeugier, P. (2015) · Future Oncology · doi:10.2217/fon.15.57 · Cited by 76
Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma
Wu, H., Wang, W., Liu, F., Weisberg, E., Tian, B., Chen, Y., Li, B., Wang, A., Wang, B., Zhao, Z., et al. (2014) · ACS Chemical Biology · doi:10.1021/cb4008524 · Cited by 77
Nicolson, P. L. R., Hughes, C. E., Watson, S., Nock, S. H., Hardy, A. T., Watson, C. N., Montague, S. J., Clifford, H., Huissoon, A. P., Malcor, J.-D. M., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.193391 · Cited by 76
Therapeutic options for relapsed/refractory mantle cell lymphoma
Eyre, T. A., Cheah, C. Y., & Wang, M. L. (2021) · Blood · doi:10.1182/blood.2021013326 · Cited by 75
Self-citationMarostica, E., Sukbuntherng, J., Loury, D. J., de Jong, J., de Trixhe, X. W., Vermeulen, A., Nicolao, G. D., O'Brien, S. M., Byrd, J. C., Advani, R. H., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2617-3 · Cited by 76
Self-citationBruton Tyrosine Kinase Is a Therapeutic Target in Stem-like Cells from Multiple Myeloma
Yang, Y., Shi, J., Gu, Z., Salama, M. E., Das, S., Wendlandt, E. B., Xu, H., Huang, J., Yi, T., Hao, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2362 · Cited by 76
High incidence of atrial fibrillation in patients treated with ibrutinib
Baptiste, F., Cautela, J., Ancedy, Y., Resseguier, N., Aurran, T., Farnault, L., Escudier, M., Ammar, C., Gaubert, M., Dolladille, C., et al. (2019) · Open Heart · doi:10.1136/openhrt-2019-001049 · Cited by 76
CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma
Mohanty, A. R., Sandoval, N., Das, M., Pillai, R. K., Chen, L., Chen, R. W., Amin, H. M., Wang, M. L., Marcucci, G., Weisenburger, D. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12434 · Cited by 78
Self-citationde Vries, R., Smit, J. W., Hellemans, P., Jiao, J. J., Murphy, J., Skee, D. M., Snoeys, J., Sukbuntherng, J., Vliegen, M., Zwart, L. D., et al. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12787 · Cited by 74
Takahashi, K., Sivina, M., Hoellenriegel, J., Oki, Y., Hagemeister, F. B., Fayad, L., Romaguera, J. E., Fowler, N. H., Fanale, M. A., Kwak, L. W., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13659 · Cited by 74
Self-citationMantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents
Inamdar, A. A., Goy, A. H., Ayoub, N. M., Attia, C., Oton, L., Taruvai, V., Costales, M., Lin, Y., Pecora, A. L., & Suh, K. S. (2016) · Oncotarget · doi:10.18632/oncotarget.8961 · Cited by 74
Self-citationEpperla, N., Hamadani, M., Cashen, A. F., Ahn, K. W., Oak, E., Kanate, A. S., Calzada, O., Cohen, J. B., Farmer, L., Ghosh, N., et al. (2017) · Hematological Oncology · doi:10.1002/hon.2380 · Cited by 71
Phase 2 study of ibrutinib in classic and variant hairy cell leukemia
Rogers, K. A., Andritsos, L. A., Wei, L., McLaughlin, E. M., Ruppert, A. S., Anghelina, M. I., Blachly, J. S., Call, T. G., Chihara, D., Dauki, A. M., et al. (2021) · Blood · doi:10.1182/blood.2020009688 · Cited by 76
Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system
Cheong, T.-C., Compagno, M., & Chiarle, R. (2016) · Nature Communications · doi:10.1038/ncomms10934 · Cited by 73
The landscape of new drugs in lymphoma
Younes, A., Ansell, S. M., Fowler, N. H., Wilson, W. H., de Vos, S., Seymour, J. F., Advani, R. H., Forero, A., Morschhauser, F., Kersten, M. J., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.205 · Cited by 73
Self-citationNastoupil, L. J., Lunning, M. A., Vose, J. M., Schreeder, M. T., Siddiqi, T., Flowers, C. R., Cohen, J. B., Burger, J. A., Wierda, W. G., O'Brien, S. M., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30216-3 · Cited by 70
Robinson, S. P., Dreger, P., Caballero, D. M., Corradini, P., Geisler, C., Ghielmini, M. E. G., Gouill, S. L., Kimby, E. K., Rule, S. A., Vitolo, U., et al. (2014) · Leukemia · doi:10.1038/leu.2014.223 · Cited by 70
Self-citationB-cell receptor–driven MALT1 activity regulates MYC signaling in mantle cell lymphoma
Dai, B., Grau, M., Juilland, M., Klener, P., Höring, E., Molinský, J., Schimmack, G., Aukema, S., Hoster, E., Vogt, N., et al. (2016) · Blood · doi:10.1182/blood-2016-05-718775 · Cited by 70
Self-citationBruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas
Aalipour, A., & Advani, R. H. (2013) · British Journal of Haematology · doi:10.1111/bjh.12573 · Cited by 71
Self-citationAlexander, M. D., Culos, K. A. A., Roddy, J. V. F., Shaw, J. R., Bachmeier, C. A., Shigle, T. L., & Mahmoudjafari, Z. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.01.014 · Cited by 71
Bonsu, J. M., Guha, A., Charles, L., Yildiz, V. O., Wei, L., Baker, B., Brammer, J. E., Awan, F. T., Lustberg, M. B., Reinbolt, R. E., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.059 · Cited by 70
Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma
Mian, A., & Hill, B. T. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1889510 · Cited by 68
Zhang, S., Jiang, C., Han, G., Hao, D., Lian, J., Liu, Y., Cai, Q., Zhang, R., McIntosh, J. M., Wang, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22872-z · Cited by 68
Self-citationTargeting Gatekeeper Mutations for Kinase Drug Discovery
Zhou, Y., Xiang, S., Yang, F., & Lu, X. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01361 · Cited by 69
Green, D. J., Shadman, M. S., Jones, J. C., Frayo, S. L., Kenoyer, A. L., Hylarides, M. D., Hamlin, D. K., Wilbur, D. S., Balkin, E. R., Lin, Y., et al. (2015) · Blood · doi:10.1182/blood-2014-11-612770 · Cited by 68
Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML
Zaitseva, L., Murray, M. Y., Shafat, M. S., Lawes, M. J., MacEwan, D. J., Bowles, K. M., & Rushworth, S. A. (2014) · Oncotarget · doi:10.18632/oncotarget.2479 · Cited by 69
Risk of Major Bleeding with Ibrutinib
Mock, J., Kunk, P. R., Palkimas, S., Sen, J. M., Devitt, M. E., Horton, B. J., Portell, C. A., Williams, M. E., & Maitland, H. S. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.07.287 · Cited by 68
Self-citationMedicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations
Lu, X., Smaill, J. B., & Ding, K. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00507 · Cited by 67
A review of a novel, Bruton’s tyrosine kinase inhibitor, ibrutinib
Lee, C., Rattu, M. A., & Kim, S. S. (2014) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155214561281 · Cited by 67
FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma
Li, Y.-Q., Bouchlaka, M. N., Wolff, J., Grindle, K. M., Lu, L., Qian, S., Zhong, X., Pflum, N., Jobin, P., Kahl, B. S., et al. (2016) · Oncogene · doi:10.1038/onc.2016.155 · Cited by 69
Self-citationCardiac side effects of bruton tyrosine kinase (BTK) inhibitors
Tang, C. P. S., McMullen, J. R., & Tam, C. S. L. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1375110 · Cited by 67
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding
Boriani, G., Corradini, P., Cuneo, A., Falanga, A., Foà, R., Gaïdano, G., Ghia, P., Martelli, M., Marasca, R., Massaia, M., et al. (2018) · Hematological Oncology · doi:10.1002/hon.2503 · Cited by 68
Chang, J. E., Li, H., Smith, M. R., Gascoyne, R. D., Paietta, E. M., Yang, D. T., Advani, R. H., Horning, S. J., & Kahl, B. S. (2014) · Blood · doi:10.1182/blood-2013-08-523845 · Cited by 66
Self-citationDietrich, S., Boumendil, A., Finel, H., Avivi, I. M., Volin, L., Cornelissen, J. J., Jarosinska, R. J., Schmid, C., Finke, J., Stevens, W. B. C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu097 · Cited by 66
Genetic landscape and deregulated pathways in B‐cell lymphoid malignancies
Rosenquist, R., Beà, S., Du, M., Nadel, B., & Pan‐Hammarström, Q. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12633 · Cited by 67
Multi-tiered chemical proteomic maps of tryptoline acrylamide–protein interactions in cancer cells
Njomen, E., Hayward, R. E., DeMeester, K. E., Ogasawara, D., Dix, M. M., Nguyen, T., Ashby, P., Simon, G. M., Schreiber, S. L., Melillo, B. N., et al. (2024) · Nature Chemistry · doi:10.1038/s41557-024-01601-1 · Cited by 68
Zhang, L. Y., Nomie, K. J., Zhang, H., Bell, T., Pham, L., Kadri, S., Segal, J. P., Li, S., Zhou, S., Santos, D. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2703 · Cited by 65
Self-citationIncidence and survival trends in mantle cell lymphoma
Epperla, N., Hamadani, M., Fenske, T. S., & Costa, L. J. (2017) · British Journal of Haematology · doi:10.1111/bjh.14699 · Cited by 65
Jain, P., Romaguera, J. E., Srour, S. A., Lee, H. J., Hagemeister, F. B., Westin, J. R., Fayad, L., Samaniego, F., Badillo, M., Zhang, L., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15411 · Cited by 64
Self-citationRobinson, S. P., Boumendil, A., Finel, H., Peggs, K. S., Chevallier, P., Sierra, J., Finke, J., Poiré, X., Maillard, N., Milpied, N. J., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-017-0067-3 · Cited by 64
Lee, J., Zhang, L. L., Wu, W., Guo, H., Li, Y., SUKHANOVA, M. J., Venkataraman, G., Huang, S., Zhang, H., Alikhan, M. B., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018016048 · Cited by 64
Self-citationBTK inhibitors: past, present, and future
Cool, A., Nong, T., Montoya, S., & Taylor, J. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.06.006 · Cited by 63
Giné, E., la Cruz, F. D., Ubieto, A. J., López‐Jiménez, J., Martı́n, A., Terol, M. J., González-Barca, E. M., Casanova, M., de la Fuente, A., Marín‐Niebla, A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02321 · Cited by 63
Dreyling, M. H., Goy, A., Hess, G., Kahl, B. S., Hernández‐Rivas, J., Schuier, N., Qi, K., Deshpande, S., Zhu, A., Parisi, L., et al. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000712 · Cited by 63
Self-citationHamasy, A., Wang, Q., Blomberg, K. E. M., Mohammad, D. K., Yu, L., Vihinen, M., Berglöf, A., & Smith, C. I. E. (2017) · Leukemia · doi:10.1038/leu.2016.153 · Cited by 62
Mantle cell lymphoma—Update on molecular biology, prognostication and treatment approaches
Silkenstedt, E., & Dreyling, M. H. (2023) · Hematological Oncology · doi:10.1002/hon.3149 · Cited by 62
Self-citationIbrutinib‐associated rash: a single‐centre experience of clinicopathological features and management
Iberri, D. J., Kwong, B. Y., Stevens, L. A., Coutre, S. E., Kim, J., Sabile, J. M. G., & Advani, R. H. (2016) · British Journal of Haematology · doi:10.1111/bjh.14302 · Cited by 62
Self-citationWang, M. L., Schuster, S. J., Phillips, T. J., Lossos, I. S., Goy, A. H., Rule, S. A., Hamadani, M., Ghosh, N., Reeder, C. B., Barnett, E., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0537-5 · Cited by 62
Self-citationOpportunities and Challenges of Small Molecule Induced Targeted Protein Degradation
He, M., Lv, W., & Rao, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.685106 · Cited by 63
Maffei, R., Fiorcari, S., Martinelli, S., Potenza, L., Luppi, M., & Marasca, R. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0157-x · Cited by 63
Hogan, J. J., & Weiss, B. M. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03160316 · Cited by 62
Targeting Bruton's tyrosine kinase with ibrutinib in B‐cell malignancies
Wang, Y., Zhang, L., Champlin, R., & Ml, W. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.85 · Cited by 60
Self-citationT-Cell Levels Are Prognostic in Mantle Cell Lymphoma
Nygren, L., Wasik, A. M., Baumgartner-Wennerholm, S., Jeppsson-Ahlberg, Å., Klimkowska, M., Andersson, P., Buhrkuhl, D., Christensson, B., Kimby, E. K., Wahlin, B. E., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0889 · Cited by 60
HLA mismatching as a strategy to reduce relapse after alternative donor transplantation
Fleischhauer, K., & Beelen, D. W. (2016) · Seminars in Hematology · doi:10.1053/j.seminhematol.2016.01.010 · Cited by 60
Metadata
- Authors
- Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., Barrientos, J. C., Chmielowska, E., Radford, J., Stilgenbauer, S., Dreyling, M., Jedrzejczak, W. W., Johnson, P., Spurgeon, S. E., Li, L., Zhang, L., Newberry, K., Ou, Z., Cheng, N., Fang, B., McGreivy, J., Clow, F., Buggy, J. J., Chang, B. Y., Beaupre, D. M., Kunkel, L. A., & Blum, K. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Derriford Hospital (GB)
- Weill Cornell Medicine (US)
- Hackensack University Medical Center (US)
- University of Wisconsin–Madison (US)
- Jagiellonian University (PL)
- Stanford Medicine (US)
- University of Virginia (US)
- Northwell Health (US)
- Centrum Onkologii (PL)
- University of Manchester (GB)
- University Hospital Ulm (DE)
- LMU Klinikum (DE)
- Cancer Research UK (GB)
- Oregon Health & Science University (US)
- Pharmacyclics (United States) (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- ORCID
- Wang, Michael L.
- Rule, Simon
- Martin, Peter
- Goy, Andre
- Auer, Rebecca
- Kahl, Brad S.
- Jurczak, Wojciech
- Advani, Ranjana H.
- Romaguera, Jorge E.
- Williams, Michael E.
- Barrientos, Jacqueline C.
- Radford, John
- Stilgenbauer, Stephan
- Dreyling, Martin
- Johnson, Peter
- Spurgeon, Stephen E.
- Li, Lei
- Zhang, Liang
- Newberry, Kate
- Fang, Bingliang
- Chang, Betty Y.
- Blum, Kristie A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-08-08
- Volume
- 369
- Issue
- 6
- Pages
- 507-516
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4513941
- OpenAlex
- W2154066874
- Cited by
- 1,685
- References
- 39
- Citations by year
- 2026: 59 · 2025: 67 · 2024: 91 · 2023: 115 · 2022: 142 · 2021: 127 · 2020: 138 · 2019: 127 · 2018: 141 · 2017: 161 · 2016: 133 · 2015: 189 · 2014: 147 · 2013: 42
- FWCI
- 127.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Funders
- American Society of Hematology
- Amgen
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Gilead Sciences
- Celgene
- Massachusetts Medical Society
- Les Laboratories Pierre Fabre
- Genentech
- Pharmacyclics
- National Cancer Institute (P30CA014520)
- Janssen Biotech
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
- Keywords
- ibrutinib, BTK inhibitors, mantle cell lymphoma, relapsed/refractory lymphoma, bortezomib, B cell receptor signaling, oral BTK inhibitor, overall response rate, progression-free survival, overall survival, adverse events, neutropenia
- MeSH terms
- Agammaglobulinaemia Tyrosine Kinase, Adenine, Administration, Oral, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Recurrence, Survival Analysis, Lymphocyte Count, Drug Resistance, Neoplasm, Lymphoma, Mantle-Cell, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
